A(f)MAZE-CABG Study

NCT ID: NCT00735722

Last Updated: 2019-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Concomitant AF ablation with HIFU in patients with persistent or long standing persistent AF undergoing CABG will be superior in restoring SR, compared with patients with persistent or long standing persistent AF undergoing CABG treated with best medical treatment according to ACC/AHA/ESC 2006 guidelines and no AF ablation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective

• To compare the efficacy of concomitant AF ablation using HIFU to no ablation at 12 months in patients with persistent or long standing persistent AF undergoing CABG according to ACC/AHA/ESC 2006 guidelines and HRS/EHRA/ECAS Consensus Statement on Catheter and Surgical Ablation .

Secondary Objectives

* To compare the safety of concomitant AF ablation using HIFU to no ablation in patients with persistent or long standing persistent AF undergoing CABG.
* To compare AF burden in patients with persistent or long standing persistent AF treated with concomitant HIFU AF ablation undergoing CABG to those receiving no ablation.
* To compare the quality of life of patients with persistent or long standing persistent AF treated with concomitant HIFU AF ablation undergoing CABG to those receiving no ablation.
* To compare the health economic impact of concomitant AF ablation with HIFU in patients with persistent or long standing persistent AF undergoing CABG to those receiving no ablation.
* To compare the morbidity associated with persistent or long standing persistent AF in patients following CABG and ablation compared to those receiving no ablation.
* To compare cardiac function and left atrial transport associated with persistent or long standing persistent AF patients following CABG and ablation compared to those receiving no ablation.
* To document the incidence of immediate post ablation bidirectional conduction block through the pulmonary venous cinch and mitral lines.
* To document the effect of Intra-operative pre and post ablation stimulation and ablation of the autonomic ganglia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Arteriosclerosis Atrial Fibrillation Coronary Artery Bypass Graft Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Concomitant HIFU ablation

HIFU AF Ablation

Group Type ACTIVE_COMPARATOR

HIFU AF Ablation

Intervention Type DEVICE

Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)

Best medical treatment

Best medical treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HIFU AF Ablation

Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

• Epicor™ UltraCinch™ LP Ablation Device • Epicor™ UltraWand™ LP Tissue Ablation Wand • Epicor™ LP Positioning and Sizing (LP PAS™) System • Epicor™ LP Oblique Introducer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Legal age in host country
* Scheduled for CABG surgery
* Patient suffering from persistent or long-standing persistent AF
* Patients having the ability to fully comply with the study requirements
* Life expectancy \> 2 years
* Patients who have given written informed consent to participate in the study

Exclusion Criteria

* Clinically significant local or systemic infection or active endocarditis
* Sutures, pacing/defibrillator leads on the left side of the heart, valve prostheses or rings, or other implanted material in or adjacent to target treatment area.
* Stent in the coronary artery preventing an adequate mitral line
* Any other concomitant operation on the heart
* Previous heart surgery
* Patients who are or may potentially be pregnant
* Previous catheter ablation for atrial arrhythmia
* LA size more than 60 mm in apical view on Trans-Thoracic Echocardiogram (TTE)
* LA thrombus on intra-operative Trans-Oesophageal Echocardiogram (TOE)
* Known contraindication to Amiodarone
* Inability to undergo TOE
* Patients who are unable to give full informed consent for the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Malcolm Dalrymple-Hay, Mr.

Role: PRINCIPAL_INVESTIGATOR

Derriford Hospital, Plymouth, United Kingdom

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Queen Elisabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status

Tampere University Hospital

Tampere, Western Finland, Finland

Site Status

Herzzentrum Essen

Essen, North Rhine-Westphalia, Germany

Site Status

Universitatsklinikum Schleswig Holstein Campus Luebeck

Lübeck, Schleswig-Holstein, Germany

Site Status

Catharina Ziekenhuis

Eindhoven, North Brabant, Netherlands

Site Status

Feiringklinikken

Feiring, , Norway

Site Status

Rikshospitalet

Oslo, , Norway

Site Status

Derriford Hospital

Plymouth, Devon, United Kingdom

Site Status

Southampton University Hospital

Southampton, Hampshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Finland Germany Netherlands Norway United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AF07004AF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FREEZE Cohort Study
NCT01360008 COMPLETED
AF Ablation for HF With Reduced EF
NCT05827172 COMPLETED NA